Ritter Pharmaceuticals To Present at Noble Capital Markets’ Fifteenth Annual Investor/Equity Conference on January 28, 2019...
2019年1月23日 - 10:30PM
Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a developer of innovative
therapeutic products that modulate the gut microbiome to treat
gastrointestinal diseases with an initial focus on the development
of RP-G28, a drug candidate with the potential to be the first
FDA-approved treatment for lactose intolerance (LI), today
announced that Andrew Ritter, CEO, will be a featured presenter at
NobleConXV - Noble Capital Markets’ Fifteenth Annual Investor
Conference on January 28th at the W Hotel, Fort Lauderdale,
Florida. Mr. Ritter will provide an overview of the company's Phase
3 program in lactose intolerance, including its pivotal Phase 3
trial, “Liberatus” which is currently underway, and other important
business highlights.
Ritter Pharmaceuticals expects to achieve major
milestones in 2019, including the completion and data readout of
its first pivotal phase 3 trial in lactose intolerance which is
expected in the second half of 2019. In December 2018, the Company
announced that it had reached the halfway-mark for enrollment in
this trial. The 525-subject multicenter, randomized, double-blind,
placebo-controlled, parallel-group study continues to enroll
on-time. Persons interested in participating in the Liberatus study
may receive more information by visiting www.clinicaltrials.gov
(NCT03597516) or by visiting
www.liberatusstudy.com/clinical-research.
A video webcast of the presentation will be
available the following day on the Company's website at:
www.ritterpharma.com. The webcast and presentation will be archived
on the company's website for 90 days following the event.
About Ritter
PharmaceuticalsRitter Pharmaceuticals, Inc.
(www.ritterpharma.com, @RitterPharma) develops innovative
therapeutic products that modulate the gut microbiome to treat
gastrointestinal diseases. The Company’s lead product candidate,
RP-G28, has the potential to become the first FDA-approved
treatment for lactose intolerance, a condition that affects
millions worldwide. RP-G28 is in Phase 3 clinical development with
its first Phase 3 clinical trial, known as “Liberatus,” currently
underway. The Company is further exploring the therapeutic
potential that gut microbiome changes may have on
treating/preventing a variety of diseases including:
gastrointestinal diseases, cancer, metabolic, and liver disease.
About Noble Capital Markets, Inc.2019 marks Noble
Capital Markets’ 35th anniversary. The Company is an
equity-research driven, full-service, investment & merchant
banking boutique focused on emerging growth companies. In addition
to NobleCon, Noble hosts numerous “non-deal” corporate road shows
across the United States and Canada. In late 2018, Noble
launched Channelchek.com which features advanced market
data, institutional-quality research, balanced news, videos and
podcasts covering more than 6,000 emerging growth companies. There
is no cost for investors to join. Members: FINRA, SIPC,
MSRB. www.noblecapitalmarkets.com
Forward-Looking StatementsThis
press release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that express the current beliefs and expectations of Ritter
Pharmaceuticals’ management. Any statements contained herein that
do not describe historical facts are forward-looking statements.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results, performance and achievements to
differ materially from those discussed in such forward-looking
statements. Some of the factors that could affect our actual
results are included in the periodic reports on Form 10-K and Form
10-Q that we file with the Securities and Exchange Commission.
Ritter cautions readers not to place undue reliance on any
forward-looking statements, which speak only as of the date they
were made. The Company undertakes no obligation to update or revise
forward-looking statements, except as otherwise required by law,
whether as a result of new information, future events or
otherwise.
ContactsInvestor Contact:John Beck 310-203-1000
john@ritterpharma.com
Media Contact:Jules Abraham
CoreIR917-885-7378julesa@coreir.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024